Characterization of a human B lymphocyte-specific antigen - PubMed (original) (raw)
. 1980 Oct;125(4):1678-85.
- PMID: 6157744
Characterization of a human B lymphocyte-specific antigen
P Stashenko et al. J Immunol. 1980 Oct.
Abstract
A human B lymphocyte-specific antigen (B1) was identified and characterized by the use of a monoclonal antibody. By indirect immunofluorescence, cytotoxicity, and quantitative absorption, B1 was present on approximately 9% of the peripheral blood mononuclear cell fraction and >95% of B cells from blood and lymphoid organs in all individuals tested. Monocytes, resting and activated T cells, null cells, and tumors of T cell and myeloid origin were B1 negative. B1 was distinct from standard B cell phenotypic markers, including Ig and Ia antigen. Removal of the B1 positive population in peripheral blood eliminated all B cells capable or responding to pokeweed mitogen by maturation to Ig-producing cells.
Similar articles
- Characterization of a human B cell-specific antigen (B2) distinct from B1.
Nadler LM, Stashenko P, Hardy R, van Agthoven A, Terhorst C, Schlossman SF. Nadler LM, et al. J Immunol. 1981 May;126(5):1941-7. J Immunol. 1981. PMID: 6163824 - A monoclonal antibody defining a lymphoma-associated antigen in man.
Nadler LM, Stashenko P, Hardy R, Schlossman SF. Nadler LM, et al. J Immunol. 1980 Aug;125(2):570-7. J Immunol. 1980. PMID: 6156208 - Xenotransplantation and ABO incompatible transplantation: the similarities they share.
Galili U. Galili U. Transfus Apher Sci. 2006 Aug;35(1):45-58. doi: 10.1016/j.transci.2006.05.007. Epub 2006 Aug 14. Transfus Apher Sci. 2006. PMID: 16905361 Review. - Flow cytometry analysis of murine B cell lymphoma differentiation.
Warner NL, Daley MJ, Richey J, Spellman C. Warner NL, et al. Immunol Rev. 1979;48:197-243. doi: 10.1111/j.1600-065x.1979.tb00304.x. Immunol Rev. 1979. PMID: 161906 Review. No abstract available.
Cited by
- Epstein-Barr virus as a potentiator of autoimmune diseases.
Robinson WH, Younis S, Love ZZ, Steinman L, Lanz TV. Robinson WH, et al. Nat Rev Rheumatol. 2024 Nov;20(11):729-740. doi: 10.1038/s41584-024-01167-9. Epub 2024 Oct 10. Nat Rev Rheumatol. 2024. PMID: 39390260 Review. - Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up.
Erdogan T, Cansu C, Kocer B, Akkaya S, Kokmen H. Erdogan T, et al. Acta Neurol Belg. 2024 Aug;124(4):1385-1391. doi: 10.1007/s13760-024-02572-3. Epub 2024 May 20. Acta Neurol Belg. 2024. PMID: 38769274 Review. - Methods for Engineering Binders to Multi-Pass Membrane Proteins.
Thomas B, Chockalingam K, Chen Z. Thomas B, et al. Bioengineering (Basel). 2023 Nov 24;10(12):1351. doi: 10.3390/bioengineering10121351. Bioengineering (Basel). 2023. PMID: 38135942 Free PMC article. Review. - Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
Schuster SJ, Huw LY, Bolen CR, Maximov V, Polson AG, Hatzi K, Lasater EA, Assouline SE, Bartlett NL, Budde LE, Matasar MJ, Koeppen H, Piccione EC, Wilson D, Wei MC, Yin S, Penuel E. Schuster SJ, et al. Blood. 2024 Feb 29;143(9):822-832. doi: 10.1182/blood.2023022348. Blood. 2024. PMID: 38048694 Free PMC article. - Pharmacogenomic Analyses Implicate B Cell Developmental Status and MKL1 as Determinants of Sensitivity toward Anti-CD20 Monoclonal Antibody Therapy.
Small GW, Akhtari FS, Green AJ, Havener TM, Sikes M, Quintanhila J, Gonzalez RD, Reif DM, Motsinger-Reif AA, McLeod HL, Wiltshire T. Small GW, et al. Cells. 2023 Jun 7;12(12):1574. doi: 10.3390/cells12121574. Cells. 2023. PMID: 37371044 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources